vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and MAXLINEAR, INC (MXL). Click either name above to swap in a different company.

MAXLINEAR, INC is the larger business by last-quarter revenue ($137.2M vs $121.8M, roughly 1.1× Core Laboratories Inc.). Core Laboratories Inc. runs the higher net margin — 4.2% vs -32.9%, a 37.1% gap on every dollar of revenue. On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs -1.4%). Over the past eight quarters, MAXLINEAR, INC's revenue compounded faster (22.1% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.

CLB vs MXL — Head-to-Head

Bigger by revenue
MXL
MXL
1.1× larger
MXL
$137.2M
$121.8M
CLB
Growing faster (revenue YoY)
MXL
MXL
+44.5% gap
MXL
43.0%
-1.4%
CLB
Higher net margin
CLB
CLB
37.1% more per $
CLB
4.2%
-32.9%
MXL
Faster 2-yr revenue CAGR
MXL
MXL
Annualised
MXL
22.1%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLB
CLB
MXL
MXL
Revenue
$121.8M
$137.2M
Net Profit
$5.1M
$-45.1M
Gross Margin
57.5%
Operating Margin
1.5%
30.0%
Net Margin
4.2%
-32.9%
Revenue YoY
-1.4%
43.0%
Net Profit YoY
-203.0%
EPS (diluted)
$0.11
$-0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
MXL
MXL
Q1 26
$121.8M
$137.2M
Q4 25
$138.3M
$136.4M
Q3 25
$134.5M
$126.5M
Q2 25
$130.2M
$108.8M
Q1 25
$123.6M
$95.9M
Q4 24
$129.2M
$92.2M
Q3 24
$134.4M
$81.1M
Q2 24
$130.6M
$92.0M
Net Profit
CLB
CLB
MXL
MXL
Q1 26
$5.1M
$-45.1M
Q4 25
$4.9M
$-14.9M
Q3 25
$14.2M
$-45.5M
Q2 25
$10.6M
$-26.6M
Q1 25
$-154.0K
$-49.7M
Q4 24
$7.4M
$-57.8M
Q3 24
$11.7M
$-75.8M
Q2 24
$9.0M
$-39.3M
Gross Margin
CLB
CLB
MXL
MXL
Q1 26
57.5%
Q4 25
20.8%
57.6%
Q3 25
22.0%
56.9%
Q2 25
20.3%
56.5%
Q1 25
19.5%
56.1%
Q4 24
17.8%
55.6%
Q3 24
20.5%
54.4%
Q2 24
21.2%
54.6%
Operating Margin
CLB
CLB
MXL
MXL
Q1 26
1.5%
30.0%
Q4 25
11.5%
-10.9%
Q3 25
15.6%
-32.7%
Q2 25
11.7%
-22.6%
Q1 25
3.6%
-48.0%
Q4 24
11.0%
-44.7%
Q3 24
14.7%
-82.3%
Q2 24
12.3%
-44.4%
Net Margin
CLB
CLB
MXL
MXL
Q1 26
4.2%
-32.9%
Q4 25
3.6%
-10.9%
Q3 25
10.6%
-36.0%
Q2 25
8.2%
-24.4%
Q1 25
-0.1%
-51.8%
Q4 24
5.7%
-62.8%
Q3 24
8.7%
-93.4%
Q2 24
6.9%
-42.7%
EPS (diluted)
CLB
CLB
MXL
MXL
Q1 26
$0.11
$-0.52
Q4 25
$0.11
$-0.17
Q3 25
$0.30
$-0.52
Q2 25
$0.22
$-0.31
Q1 25
$0.00
$-0.58
Q4 24
$0.15
$-0.68
Q3 24
$0.25
$-0.90
Q2 24
$0.19
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
MXL
MXL
Cash + ST InvestmentsLiquidity on hand
$22.8M
$61.1M
Total DebtLower is stronger
$123.8M
Stockholders' EquityBook value
$275.1M
$454.2M
Total Assets
$587.7M
$771.3M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
MXL
MXL
Q1 26
$22.8M
$61.1M
Q4 25
$22.7M
$72.8M
Q3 25
$25.6M
$111.9M
Q2 25
$31.2M
$108.6M
Q1 25
$22.1M
$102.8M
Q4 24
$19.2M
$118.6M
Q3 24
$21.5M
$148.5M
Q2 24
$17.7M
$185.1M
Total Debt
CLB
CLB
MXL
MXL
Q1 26
$123.8M
Q4 25
$110.3M
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
Q3 24
$139.9M
Q2 24
$147.6M
Stockholders' Equity
CLB
CLB
MXL
MXL
Q1 26
$275.1M
$454.2M
Q4 25
$266.0M
$451.9M
Q3 25
$271.3M
$464.7M
Q2 25
$261.3M
$488.3M
Q1 25
$253.4M
$493.2M
Q4 24
$246.6M
$516.3M
Q3 24
$250.7M
$556.9M
Q2 24
$240.3M
$617.3M
Total Assets
CLB
CLB
MXL
MXL
Q1 26
$587.7M
$771.3M
Q4 25
$584.0M
$796.4M
Q3 25
$591.4M
$808.1M
Q2 25
$602.1M
$863.7M
Q1 25
$591.5M
$855.3M
Q4 24
$585.1M
$864.6M
Q3 24
$600.5M
$895.3M
Q2 24
$597.8M
$973.2M
Debt / Equity
CLB
CLB
MXL
MXL
Q1 26
0.27×
Q4 25
0.41×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.56×
Q2 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
MXL
MXL
Operating Cash FlowLast quarter
$4.0M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
MXL
MXL
Q1 26
$4.0M
Q4 25
$7.9M
$10.4M
Q3 25
$8.5M
$10.1M
Q2 25
$13.9M
$10.5M
Q1 25
$6.7M
$-11.4M
Q4 24
$20.6M
$-27.8M
Q3 24
$13.1M
$-30.7M
Q2 24
$17.1M
$-2.7M
Free Cash Flow
CLB
CLB
MXL
MXL
Q1 26
$517.0K
Q4 25
$5.0M
$6.7M
Q3 25
$6.5M
$4.4M
Q2 25
$10.4M
$9.3M
Q1 25
$3.9M
$-13.4M
Q4 24
$17.4M
$-30.0M
Q3 24
$10.4M
$-34.9M
Q2 24
$14.3M
$-5.7M
FCF Margin
CLB
CLB
MXL
MXL
Q1 26
0.4%
Q4 25
3.6%
4.9%
Q3 25
4.8%
3.5%
Q2 25
8.0%
8.6%
Q1 25
3.1%
-14.0%
Q4 24
13.4%
-32.6%
Q3 24
7.7%
-43.0%
Q2 24
10.9%
-6.2%
Capex Intensity
CLB
CLB
MXL
MXL
Q1 26
Q4 25
2.1%
2.7%
Q3 25
1.5%
4.5%
Q2 25
2.7%
1.1%
Q1 25
2.3%
2.1%
Q4 24
2.5%
2.4%
Q3 24
2.0%
5.1%
Q2 24
2.2%
3.3%
Cash Conversion
CLB
CLB
MXL
MXL
Q1 26
0.77×
Q4 25
1.61×
Q3 25
0.60×
Q2 25
1.31×
Q1 25
Q4 24
2.78×
Q3 24
1.12×
Q2 24
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons